Skip to main content

Pediatrix Medical Group, Inc. (MD) Stock Analysis

Range Bound setup

SellModerate Confidence

Healthcare · Medical Care Facilities

Earnings in 5 days (2026-05-05). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Sell if holding. Analyst target reached at $22.41 — A.R:R is negative (-1.5) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Earnings in 5 days (event risk).

Pediatrix Medical Group is a national physician services provider with approximately 2,295 affiliated physicians across 37 states, primarily in NICU neonatal care (1,350 physicians in 360+ NICUs), maternal-fetal medicine, and pediatric subspecialty care. Revenue comes from... Read more

$22.41+3.6% A.UpsideScore 5.1/10#20 of 27 Medical Care Facilities
Stop $20.89Target $23.21(resistance)A.R:R -1.5:1
Analyst target$22.17-1.1%6 analysts
$23.21our TP
$22.41price
$22.17mean
$19
$27

Sell if holding. Analyst target reached at $22.41 — A.R:R is negative (-1.5) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Earnings in 5 days (event risk). Chart setup: RSI 60 mid-range, Bollinger mid-band. Score 5.1/10, moderate confidence.

Passes 4/7 gates (clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and earnings proximity 5d<=7d. Suitability: aggressive.

Thesis

Rewards
Strong earnings beat streak (3/4)
Attractive valuation
Risks
Analyst target reached - limited upside remaining
Earnings in 5 days (event risk)
Weak growth

Key Metrics

P/E (TTM)11.5
P/E (Fwd)9.6
Mkt Cap$1.9B
EV/EBITDA7.7
Profit Mgn8.6%
ROE20.3%
Rev Growth-1.7%
Beta0.72
DividendNone
Rating analysts15

Quality Signals

Piotroski F7/9

Options Flow

P/C0.88neutral
IV102%elevated
Max Pain$10-55.4% vs spot

Concentration Risks(10-K Item 1A)

  • MEDIUMGeographicTexas32%
    10-K Item 1A: 'Texas accounted for approximately 32% of our net revenue in 2025.'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

3 floor-breakers

Revenue shrinking — -1.7% YoY. Growth thesis broken unless recovery story develops.static

Revenue Growth
2.1
Earnings Growth
4.3
Declining revenue: -2%

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Growth Rank
0.4
Value Rank
6.6
Quality Rank
7.2
Best-in-class margins

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Volume
0.0
Obv
1.0
Macd
2.7
Rsi
5.5
Ma Position
9.0
Volume distribution (falling OBV)Above 200-day MA
GatesMomentum 3.6<4.5A.R:R -1.5=NEGATIVEEARNINGS PROXIMITY 5d<=7dInsider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARRange BoundSuitability: Aggressive
RSI
60 · Neutral
20D MA 50D MA 200D MAGOLDEN CROSSSupport $20.33Resistance $23.68

Price Targets

$21
$23
A.Upside+3.6%
A.R:R-1.5:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeCautious

Risk Alerts

! Target reached (-13.9% upside)
! Momentum score 3.6/10 — below 4.5 minimum
! Negative risk/reward — downside exceeds upside

Earnings

B
B
B
M
3/4 beats
Next Earnings2026-05-05 (5d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is MD stock a buy right now?

Sell if holding. Analyst target reached at $22.41 — A.R:R is negative (-1.5) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Earnings in 5 days (event risk). Chart setup: RSI 60 mid-range, Bollinger mid-band. Prior stop was $20.89. Score 5.1/10, moderate confidence.

What is the MD stock price target?

Take-profit target: $23.21 (+3.6% upside). Prior stop was $20.89. Stop-loss: $20.89.

What are the risks of investing in MD?

Analyst target reached - limited upside remaining; Earnings in 5 days (event risk); Weak growth.

Is MD overvalued or undervalued?

Pediatrix Medical Group, Inc. trades at a P/E of 11.5 (forward 9.6). TrendMatrix value score: 7.5/10. Verdict: Sell.

What do analysts say about MD?

15 analysts cover MD with a consensus score of 3.9/5. Average price target: $22.

What does Pediatrix Medical Group, Inc. do?Pediatrix Medical Group is a national physician services provider with approximately 2,295 affiliated physicians across...

Pediatrix Medical Group is a national physician services provider with approximately 2,295 affiliated physicians across 37 states, primarily in NICU neonatal care (1,350 physicians in 360+ NICUs), maternal-fetal medicine, and pediatric subspecialty care. Revenue comes from physician services reimbursed by government healthcare programs and commercial payors.

Related stocks: UHS (Universal Health Services, Inc.) · AVAH (Aveanna Healthcare Holdings Inc) · ADUS (Addus HomeCare Corporation) · ASTH (Astrana Health Inc.) · CON (Concentra Group Holdings Parent)